Hello, everybody. It’s a pleasure for me to be here today and to have the chance to collaborate with Medscape in this quite interesting series about melanoma. For this first video, I want to introduce myself and let you know a little bit about my passion for melanoma investigation, and also why this is important to continue speaking about in the next couple of years.
2025
RELATIVITY-047: Extended Analysis Of Overall Survival With Nivolumab/Relatlimab vs Nivolumab In Previously Untreated Advanced Melanoma
In an extended analysis of the phase II/III RELATIVITY-047 trial reported in the Journal of Oncology, Tawbi et al found a significant overall survival benefit with nivolumab/relatlimab vs nivolumab in previously untreated patients with unresectable advanced stage III or IV melanoma.
AI Shows Promise in Skin Cancer Detection, But Clinical Validation Still Needed
Scientists in the East of England have developed a way of using artificial intelligence to check for skin cancer, with the AI tool outperforming existing methods in a new study.
Melanoma tumors thicker than 0.8 mm increase risk for death
The crude incidence rate of melanoma-related death 20 years after diagnosis was 6% for those with tumors thinner than 0.8 mm.